Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCTBiotechnology
+$0.15 today
- Market cap
- $231.73M
- Beta
- 2.35
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$2.77
Volume 0.64M
Average 0.43M
ARCT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $20.93M fell 40.0% year over year, ahead of the -44.3% change in trailing-twelve-month research & development. Sequentially, it fell 14.5% from the prior quarter. Over 3 fiscal years it compounded at -8.8% a year.
Context
- Research & development amounted to 166.9% of revenue in FY2025, up 25.9 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -40.0% holds above the trailing-twelve-month pace of -44.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 112.21M USD
- Year-over-year change
- -42.5%
- 4-year CAGR
- -10.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 112.21M | -42.5% |
| FY2024 | 2024-12-31 | 195.16M | +1.6% |
| FY2023 | 2023-12-31 | 192.13M | +30.0% |
| FY2022 | 2022-12-31 | 147.75M | -15.0% |
| FY2021 | 2021-12-31 | 173.76M | — |
Research & Development vs competitors
How ARCT compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -44.3% is the 9th highest of 10, against a peer median of -10.9%.
- Research & development amounts to 216.6% of revenue for ARCT, versus a peer median of 193.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $446.24M USD | -15.0% | -3.0% | 681.3% | |
| LTM Mar 2026 | $345.36M USD | -10.9% | -35.2% | 57.9% | |
| LTM Mar 2026 | $159.57M USD | +37.4% | +18.6% | — | |
| LTM Mar 2026 | $137.53M USD | -14.3% | -5.0% | — | |
| LTM Mar 2026 | $98.25M USD | -44.3% | -8.8% | 216.6% | |
| LTM Mar 2026 | €85.57M EUR | +12.6% | -6.7% | 54.7% | |
| LTM Mar 2026 | $61.84M USD | — | +24.0% | 6710.8% | |
| LTM Mar 2026 | $51.51M USD | -27.2% | -33.9% | — | |
| LTM Mar 2026 | €44.34M EUR | +12.6% | -7.1% | 329.9% | |
| LTM Mar 2026 | $20.4M USD | -57.1% | -33.1% | 10.7% | |
| LTM Mar 2026 | $19.2M USD | +1.2% | +17.6% | — | |
| Peer median (excluding ARCT) | — | -10.9% | -5.8% | 193.9% | |
Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.36M | 205.76M | 157.75M | 138.39M | 67.22M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.03M |
| Gross Profit | 12.36M | 205.76M | 157.75M | 138.39M | 64.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 95.5% |
| Research & Development | 173.76M | 147.75M | 192.13M | 195.16M | 112.21M |
| Selling, General & Admin | 41.45M | 46.07M | 52.87M | 52.82M | 46.08M |
| Operating Expenses | 215.21M | 193.58M | 235.95M | 234.06M | 139.15M |
| Depreciation & Amortization | 1.19M | 1.53M | 2.96M | 3.54M | 3.03M |
| EBITDA | (199.81M) | 15.17M | (24.17M) | (77.4M) | (62.76M) |
| EBITDA Margin | -1616.7% | 7.4% | -15.3% | -55.9% | -93.4% |
| Operating Income | (202.85M) | 12.18M | (78.21M) | (95.67M) | (74.96M) |
| Operating Margin | -1641.3% | 5.9% | -49.6% | -69.1% | -111.5% |
| Interest Income | 753K | 2.58M | 17.36M | 15.2M | 10.1M |
| Interest Expense | 2.67M | 3M | 767K | 0 | 0 |
| Other Income / Expenses | (822K) | (1.53M) | 50.32M | 14.72M | 9.17M |
| Income Before Tax | (203.67M) | 10.64M | (27.89M) | (80.95M) | (65.78M) |
| Pre-Tax Margin | -1648.0% | 5.2% | -17.7% | -58.5% | -97.9% |
| Income Tax Expense | 0 | 1.3M | 1.84M | (4K) | 0 |
| Net Income | (203.67M) | 9.35M | (29.73M) | (80.94M) | (65.78M) |
| Net Margin | -1648.0% | 4.5% | -18.8% | -58.5% | -97.9% |
| EPS (Basic) | (7.74) | 0.35 | (1.12) | (3.00) | (2.40) |
| EPS (Diluted) | (7.74) | 0.35 | (1.12) | (3.00) | (2.40) |
| Weighted Avg Shares | 26.32M | 26.45M | 26.63M | 27M | 27.39M |
| Weighted Avg Shares (Diluted) | 26.32M | 27.09M | 26.63M | 27M | 27.39M |
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
Intrinsic Alpha fair value
Locked
Current Price
$8.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.